2018年
- December 27, 2018
- Hebrew University to Collaborate with KYORIN Strategic partnership aims to develop respiratory drug therapies
- November 20, 2018
- Launch of "Beova® Tablets 50mg" for the Treatment of Overactive Bladder
- November 5, 2018
- Summary of Consolidated Financial Results (For the Second Quarter Ended September 30, 2018) [Japanese Standard]
- November 5, 2018
- Second Quarter Consolidated Financial Results for the Fiscal Year Ending March 31, 2019
- November 5, 2018
- Notice Regarding the Cancellation of Treasury Stock
- November 2, 2018
- Revision of Consolidated Financial Forecasts
- September 27, 2018
- Notice on Results and Completion of Acquisition of Treasury Stock through Off-Floor Trading for Purchase of Treasury Stock (ToSTNeT-3) and Change to Major Shareholder
- September 26, 2018
- Notice of Acquisition of Treasury Stock and Purchase of Treasury Stock by Off-Floor Trading for Purchase of Treasury Stock (ToSTNeT-3)
- September 21, 2018
- Kyorin Receives Marketing Approval in Japan for｢Beova Tablets 50mg｣ for the Treatment of Overactive Bladder
- August 1, 2018
- KYORIN Pharmaceutical and FAES Farma Sign Agreement on Development and Distribution of Imidafenacin in Latin America
- July 31, 2018
- Summary of Consolidated Financial Results（July 31, 2018)
- July 31, 2018
- Supplementary information (July 31, 2018)
- July 31, 2018
- Changes in Capital Policy and Shareholder Return Policy
- May 10, 2018
- Supplementary information (May 10, 2018)
- March 29, 2018
- Kyorin Pharmaceutical Sign a License Agreement for "SK-1404," a Therapeutic Agent for Nocturia Due to Nocturnal Polyuria
- 1